Syndromic Multiplex Diagnostic Markets: Global Insights & Forecasts, 2019-2023 - Syndromic Testing Displacing Physician-based Diagnostics

News provided by

Mar 15, 2019, 18:15 ET

DUBLIN, March 15, 2019 /PRNewswire/ -- The "Global Syndromic Multiplex Diagnostic Markets 2019 to 2023 - Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI etc.), by Country, with Market Analysis, Executive Guides and Customization." report has been added to ResearchAndMarkets.com's offering.

Are targeted tests for specific pathogens going to be obsolete? Will Infectious Disease testing move into the Physician's Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance.

Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time.

The report forecasts the market size out to 2023. In a special section, the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.

Topics Covered

i. Market Guides
iA. Situation Analysis
iB. Guide for Executives and Marketing Staff
iC. Guide for Investment Analysts and Management Consultants

1. Introduction and Market Definition
1.1 What are Syndromic Multiplex Tests?
1.2 Syndromic Testing - the quiet revolution in diagnostics
1.2.1 Syndromic Testing - more than Panels.
1.3 Market Definition
1.3.1 Multiplex Market Size
1.3.2 Panel Market Size
1.3.2 Currency
1.3.3 Years
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Guide to the Pathogens
2.1 HIV - Human Immunodeficiency Virus (AIDS)
2.1.1 Virology
2.1.1.1 Classification
2.1.1.2 Structure and genome
2.1.1.3 Tropism
2.1.1.4 Replication cycle
2.1.1.5 Genetic variability
2.1.2 Diagnosis
2.1.3 Testing
2.1.3.1 Antibody tests
2.1.3.2 Point of Care Tests (POCT)
2.1.3.4 Antigen Tests
2.1.3.5 Nucleic acid-based tests (NAT)
2.1.3.6 Other tests used in HIV treatment
2.2 HBV - Hepatitis B
2.2.1 Virology
2.2.1.1 Genome
2.2.1.2 Pathogenesis
2.2.1.3 Hepatitis B virus replication
2.2.1.4 Serotypes and genotypes
2.2.2 Mechanisms
2.2.3 Diagnosis
2.2.4 Market Opportunity Analysis
2.3 HCV - Hepatitis C
2.3.1 Taxonomy
2.3.2.1 Structure
2.3.2.2 Genome
2.3.3 Molecular biology
2.3.4 Replication
2.3.5 Genotypes
2.3.5.1 Clinical importance
2.3.6 Market Opportunity Analysis
2.4 HPV - Human papillomavirus
2.4.1 Virology
2.4.1.1 E6/E7 proteins
2.4.1.2 Role in cancer
2.4.1.3 E2 research
2.4.1.4 Latency period
2.4.1.5 Clearance
2.4.2 Diagnosis
2.4.2.1 Cervical testing
2.4.2.2 Oral testing
2.4.2.3 Testing men
2.4.2.4 Other testing
2.4.3 Market Opportunity Analysis
2.5 Influenza
2.5.1 Virology
2.5.1.1 Types of virus
2.5.1.2 Influenzavirus A
2.5.1.3 Influenzavirus B
2.5.1.4 Influenzavirus C
2.5.1.5 Structure, properties, and subtype nomenclature
2.5.1.6 Replication
2.5.2 Testing
2.5.2.1 Advantages/Disadvantages of Molecular Assays
2.5.3 Market Opportunity Analysis
2.6 CTGC - Chlamydia/Gonorhea
2.6.1 Gonorrhea
2.6.1.1 Diagnosis
2.6.1.2 Screening
2.6.2 Chlamydia
2.6.2.1 Diagnosis
2.6.2.2 Screening
2.6.3 Testing
2.6.3.1 Nucleic acid amplification tests (NAATs).
2.6.3.2 Performance of NAAT Tests
2.6.4 Market Opportunity Analysis
2.7 Tuberculosis
2.7.1 Mycobacteria
2.7.2 Diagnosis
2.7.2.1 Active tuberculosis
2.7.2.2 Latent tuberculosis
2.7.3 Epidemiology
2.7.4 Molecular Diagnostic Tests
2.7.5 Market Opportunity Analysis
2.8 MRSA - Methicillin-resistant Staphylococcus aureus
2.8.1 Diagnosis
2.8.2 FDA Approved Molecular Tests.
2.8.3 Market Opportunity Analysis
2.9 VRE - Vancomycin-resistant Enterococcus
2.9.1 FDA Approved MDx Tests for VRE
2.9.2 Market Opportunity Analysis

3. Industry Overview
3.1 Industry Participants
3.1.1 IVD Supplier
3.1.2 Independent lab specialized/esoteric
3.1.3 Independent lab national/regional
3.1.4 Independent lab analytical
3.1.5 Public National/regional lab
3.1.6 Hospital lab
3.1.7 Physician lab
3.1.8 Audit body
3.2 The Clinical Laboratory Market Segments
3.2.1 Traditional Market Segmentation
3.2.2 Laboratory Focus and Segmentation
3.2.3 Segmenting the Syndromic Testing Market
3.3 Industry Structure
3.3.1 Hospital Testing Share
3.3.2 Economies of Scale
3.3.2.1 Hospital vs. Central Lab
3.3.3 Physician Office Labs
3.3.4 Physician's and POCT

4. Market Trends
4.1 Factors Driving Growth
4.1.1 Speed of Diagnosis
4.1.2 Effect of Syndromic Testing on Costs
4.1.3 Point of Care Advantage
4.1.4 Syndrome Testing, Accuracy and Diagnostic Risk
4.1.5 Single Visits
4.1.6 Improvement in Outcomes
4.2 Factors Limiting Growth
4.2.1 Lower Prices
4.2.2 Infectious Disease is Declining But
4.2.3 Wellness Hurts.
4.2.4 Economic Growth improves Living Standards
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 The Shrinking Machine
4.3.3 Syndrome Testing Moving to Big Instruments?
4.4 Diagnostic Technology Development
4.4.1 Comparing Syndrome and Targeted Testing
4.4.2 The Multiplex Paradigm Shift
4.4.2 The Sepsis Testing Market - Bellwether for Syndromics
4.4.3 The Single Visit and AntiMicrobial Resistance
4.4.4 Syndromics drives POCT adoption
4.4.5 A Big Future for PCR?

5. Syndromic Testing Recent Developments
Recent Developments - Importance and How to Use This Section
Importance of These Developments
How to Use This Section

Akonni Biosystems Submits Multiplex Diagnostics System to FDA
Ador Diagnostic to receive $30M in Funding for 100-Plex PoC
SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
QuantuMDx and Molbio announce MoU
Immunexpress Wins $745K Contract for Rapid Sepsis Assay
Mobidiag Inks European, Middle Eastern Distribution Deals
BIOFIRE FILMARRAY System chosen for Phase 3 clinical trial
bioMerieux launches the BIOFIRE FILMARRAY Pneumonia Panels
XCR Diagnostics and Luminex Enter into License Agreement
Palmetto Final LCD Denies Coverage to Large Respiratory Panels
Karius Test to Be Available in Brazil
Inflammatix HostDx Fever Test able to Rapidly Distinguish Bacterial from Viral Infections
Panagene's STD kit gains Approval
GenePOC's Investment Validated by Medicare Decision
Startup Prominex Raises $4M in Series A1
Alveo Closes Financing to Create Accessible Diagnostics Devices
MBio Diagnostics, Inc. Funding Supports Scaling of PoC Testing Platform
GenePOC launches its GenePOC CDiff test in Canada
Siemens Healthineers completes takeover of Fast Track Diagnostics
Chembio and FIND to Develop Point-of-Care Multiplex Test
Applied BioCode Receives CE Mark for 18-plex Gastrointestinal Pathogen Panel
Rapid Molecular Flu Tests Gain Ground
Cepheid Receives FDA Clearance and CLIA Waiver for Xpert Xpress Flu Test
bioMerieux seeks FDA Clearance of Pneumonia Panel
Mobidiag Announces Release of a Multiplex qPCR Test for Detection of Antibiotic Resistant Bacteria
Fast Track Diagnostics Gets CE Mark for Real-Time PCR Detection of High-Risk HPV
SEEGENE develops Multiplex PCR tests in 4 days
Seegene enters the U.S. diagnostic market in collaboration with Thermo Fisher Scientific
Fusion Genomics Developing All Pathogens Diagnostic.
Anapa Biotech Announces MeltPlex Technology
First multiplex test for tick-borne diseases
ArcherDx, MGH Suing Qiagen Over Anchored Multiplex PCR Technology
Akonni Biosystems Forms Chinese Commercialization Partnership with Righton
Vela Buys Great Basin Scientific
BARDA Awards up to $30M to Cue Health for Influenza, Respiratory Pathogen Test
QIAGEN enters into agreement to acquire STAT-Dx
GA-EMS receives diagnostic device contract
Biocartis & Immunexpress Sign Partnership for Sepsis

6. Profiles of Key Syndromic Testing Companies

Abbott Diagnostics (Alere)
Accelerate Diagnostics
Ador Diagnostics
Akkoni Biosystems
Alveo Technologies
Applied BioCode
Atlas Genetics
Aus Diagnostics
BD Diagnostics
Biocartis
BioFire Diagnostics
bioMerieux
Bio-Rad Laboratories
Bosch Healthcare Solutions GmbH
Cepheid
Curetis
Diagenode Diagnostics
Diasorin
Fusion Genomics
GenePOC Diagnostics
GenMark Dx
Hologic
Inflammatix
Invetech
Janssen Diagnostics
Karius
Lexigene
Luminex
Mbio Diagnostics
Mesa Biotech
Mobidiag
Nanomix
Oxford Nanopore
Panagene
Primerdesign
Prominex
Qiagen (Statdx)
Quantumdx
Roche Molecular Diagnostics
Seegene
Sensovation
Siemens Healthineers (Fast Track Diagnostics)
SkylineDx
T2 Biosystems
Thermo Fisher
Veramarx
XCR Diagnostics

7. Global Market Size
7.1 Syndromic Global Market Size by Country with Charts
7.2 Syndromic Global Market Size by Syndrome with Charts

8. Global Market by Syndrome
8.1 Respiratory Syndrome Market
8.1.1 Respiratory Syndrome Market by Country
8.2 GI-Enteric Syndrome Market
8.2.1 GI-Enteric Market by Country with Chart
8.3 Blood-Sepsis Syndrome Market
8.3.1 Blood-Sepsis Market by Country with Chart
8.4 Meningitis Syndrome Market
8.4.1 Meningitis Market by Country with Chart
8.5 Sexually Transmitted Disease Syndrome Market
8.5.1 Sexually Transmitted Disease Market by Country with Chart
8.6 Other Syndrome Market
8.6.1 Other Market by Country with Chart

9. Panel Testing Market - Volumes and Price Forecast with MDx Share
9.1 Respiratory Panel Market
9.2 GI-Enteric Panel Market
9.3 Blood-Sepsis Panel Market
9.4 Meningitis Panel Market
9.5 Sexually Transmitted Disease Panel Market
9.6 Other Panel Market

Appendices
I. United States Medicare System: 2018 Clinical Laboratory Fees Schedule - National Limit and Midpoint
II. FDA Approved Microbial Tests

For more information about this report visit https://www.researchandmarkets.com/research/hrsb5p/syndromic?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets